Pharma's once-promising TIGIT immuno-oncology target has collapsed after costly clinical failures, leading to billions lost. Key players including Bristol Myers Squibb, Gilead, GSK, and Novartis collectively spent $1.4 billion upfront licensing TIGIT programs, with over $5 billion in milestones largely unmet due to halted developments. Gilead remains active with Arcus Biosciences’ domvanalimab, but the wider industry has pulled back sharply. Despite heavy R&D spending embedded within large companies' budgets, results underscore significant financial and strategic setbacks in TIGIT drug development programs.